Saturday 17 October 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.18
0.02
−1.67%
Follow SILO
Silo Pharma, Inc. (SILO) P/E ratio
Silo Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 7.0× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 3.5× | — |
| FY2019 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.0×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| CLSDQ Clearside Biomedical, Inc. compare | n/m |
| TRVN Trevena, Inc. compare | n/m |
| GNPX GENPREX compare | 0.0× |
| OGEN Oragenics, Inc. compare | 0.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)